1Imperatore G, Riccardi G, Iovine C, et al. Plasma fibrinogen: a new factor of the metabolic syndrome. A population-based study [ J ].Diabetes Care, 1998,21 (4) :649-654.
2Xia H, Redman C M. Oxysterols suppress constitutive fibrinogen expression [ J ]. Thromb Haemost,2003,90 ( 1 ) :43-51.
6Iwasaki T, Yoneda M, Nakajima A, et al. Serum butyrylcholinest- erase is strongly associated with adiposity,the serum lipid profile and insulin resistance[J]. Intern Med,2007,46(19) :1633-1639.
7Ogunkeye OO, Roluga AI. Serum cholinesterase activity helps to distinguish between liver disease and non-liver disease aberration in liver function tests[J]. Pathophysiology, 2006,13(2) : 91-93.
8Ogunkeye OO,Chuhwak EK, Otokwula AA. Serum cholinesterase activity in the diagnosis of nonalcoholic fatty liver disease in type 2 diabetic patients[J]. Pathophysiology, 2010,17(1) : 29-32.
10Jeevaratnam K,Sugendran K,Vaidyanathan CS. Influence of methylamine and N, N'-dimethylurea, the hydrolysis products of methyl isocyanate, on its systemic toxicity[J]. Journal of Applied Toxicology, 1900,13 (1) : 15-18.
